Please enable JS

DISCOVER

Telemedicine technologies

Our story,
our strength

Telemedicine Technologies is the publisher of e-Health solutions, market leader in the field of Clinical Research with its CleanWeb™ solution, a secure Internet platform dedicated to the electronic management of clinical trials and registries.

For over 20 years, our company has been working to facilitate clinical research and empower all kind of clinical trials all around the world. Our solution CleanWeb™ for the electronic management of phase I-IV clinical trials, registries, observational studies and early access programmes is used in more than 64 different countries, more than 5,500 studies are ongoing or have been completed on our e-platform and more than 2 million patients have already been recruited via our solution. 



From leading pharmaceutical companies to biotech start-ups and public hospitals, we are proud to support the activities of over 20,000 investigative centres and 50,000 users worldwide.

Our CleanWeb solution is ISO9001:2015 certified and compliant with the GAMP5 information system validation methodology. CDISC/ODM certified, we have been a global expert in data management for 20 years.

Our solution has an extremely high adoption rate, thanks to intuitive interfaces and our commitment to creating solutions tailored to our users’ needs. We have Qualiopi certification for training, a distinction that testifies to our constant concern for quality and customer satisfaction. In 2021 our training courses had an excellent customer satisfaction rate of 97%.

OUR TEAM

YOANNI TH. MATSAKIS
President

He is an aeronautical and space engineer (Sup’aéro), and worked for CNES (Centre National des Etudes Spatiales) and then for the MEDES (Institut de Médecine & Physiologie Spatiales), where he joined the project team of several manned space missions as Scientific and Responsible for the development of on board equipment for the astronauts physiological follow-up. Then he launched an important research and development program, which results in the creation of the company in 2000.

HUGUES GOURBAT
CEO

He is graduated from the Ecole Centrale Paris and the Business Administration Institute of the Paris University, and is a former Accenture partner. He joined the company in 2016 during the merger of TRIACYS. As General Director, he is an Executive Committee member and is responsible for the administrative, financial and human resources management.

DR. PHILIPPE HARAN
CEO and Business Development Director

Doctor, HEC graduate, Philippe brings the company his double skills. After a career in the pharmaceutical industry and as a CRO executive, he built strong experience in the field of clinical research and health innovations. He joined the company in 2016, and is an Exe

HOCINE MOKHTARI
Technical director

After graduating in computer engineering, he joined the company soon after its creation. He knows very well all the society’s applications. True expert on software development, he always has the right technical.

A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT

64 +

countries
involved

20 000 +

investigational
Centres

3 million +

patients
in database

50 000 +

users
worlwide

telemedicine technologies earth

LATEST NEWSOUR NEWS >

telemedecine technologies news

Telemedicine Technologies will be at Swiss Biotech Day 2025

April 29, 2025

May 5 & 6 – Basel Telemedicine Technologies is pleased to present its CleanWeb™ eClinical suite, offering flexible, regulatory-compliant solutions tailored to every phase of clinical trials. Our platform includes a wide range of modules, such as eCRF, Randomization & Trial Supply Management, ePRO, eTMF, eConsent, Data Visualization, Vigilance, Imaging, CTMS, and more. We invite […]

READ MORE
telemedecine technologies news

Drug development cost pharma $2.2B per asset in 2024 as GLP-1s drive financial return

April 29, 2025

Fierce Biotech The average cost for a Big Pharma to develop a drug in 2024 was $2.23 billion, up from $2.12 billion the year before. The data come from 20 pharmas that had the highest R&D budgets in 2020, as reported in Deloitte’s annual report, “Measuring the return from pharmaceutical innovation.” In 2024, the average […]

READ MORE
telemedecine technologies news

Adopting Flexible Strategies to Combat Capacity Shortages

April 29, 2025

Biopharm International In January 2025, Samsung Biologics signed a six-year, $1.4 billion contract manufacturing agreement with an as-yet undisclosed European pharmaceutical company, with production to take place at Samsung’s manufacturing site in Songdo, South Korea (1). Simultaneously, at the J.P. Morgan Healthcare Conference held in San Francisco, the company announced plans to complete construction of […]

READ MORE